// App-Quantinova.ai

OC2.2 : STOPFOP: A european phase II clinical trial using saracatinib to prevent FOP

Researchers

Presenter

  • Bernard Smilde

Principal Investigators

  • Richard Keen

  • Clemens Stockklausner

  • Dong Liu

  • Alex Bullock

  • Annette Von Delft

  • Natasja Van Schoor

  • Paul Yu

  • Elisabeth Eekhoff

Medical Centers

  • Amsterdam UMC, location VUmc, Internal Medicine section Endocrinology, Amsterdam, Netherlands

  • Royal National Orthopaedic Hospital, Department of Rheumatology, Middlesex and London, United Kingdom

  • Klinikum Garmisch-Partenkirchen GmbH Abteilung für Kinderklinik, Department of Paediatrics, Garmisch-Partenkirchen, Germany

  • Astrazeneca, Boston, United States

  • University of Oxford, Nuffield Department of Clinical Neurosciences, Oxford, United Kingdom

  • Amsterdam UMC, locatie VUmc, Epidemiology and biostatistics, Amsterdam, Netherlands

  • Brigham and Women’s Hospital - Department of Cardiovascular Medicine, Department of Medicine, Boston, United States

  • Amsterdam UMC, location VUmc, Internal Medicine section Endocrinology, Amsterdam, Netherlands

Locations

  • Netherlands

  • United Kingdom

  • Germany

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Fibrodysplasia ossificans progressiva

  • Gynaecological cancer

  • Solid malignancies

Biomarkers

  • 18F-fluorodeoxyglucose

Drug/Treatment

  • saracatinib

  • AZD-0530

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Double Blind/Blinded

  • Open Label

  • Multicenteric

  • Controlled

Phase

  • II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved